Balyasny Asset Management
PRME icon

Balyasny Asset Management’s Prime Medicine PRME Stock Holding History

Balyasny Asset Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.6M Sell
3,969,082
-154,283
-4% -$512K 0.02% 883
2026
Q1 		$14.3M Buy
4,123,365
+999,003
+32% +$3.8M 0.02% 842
2025
Q4 		$10.8M Buy
3,124,362
+3,076,489
+6,426% +$13.7M 0.01% 983
2025
Q3 		$265K Buy
+47,873
New +$194K ﹤0.01% 2628
2025
Q1 		– Sell
-16,342
Closed -$47.7K – 3189
2024
Q4 		$47.7K Buy
+16,342
New +$57.4K ﹤0.01% 2640
2024
Q3 		– Sell
-12,101
Closed -$62.2K – 3080
2024
Q2 		$62.2K Buy
+12,101
New +$73.4K ﹤0.01% 2429

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Balyasny Asset Management's PRME Position: Q2 2026 in Review

Balyasny Asset Management reduced its Prime Medicine (PRME) stake by 3.7% in Q2 2026, selling an estimated $512K and leaving 3,969,082 shares worth $14.6M. The position accounts for 0.02% of the portfolio, ranked #883.

Balyasny Asset Management first reported a position in PRME in Q2 2024 and has held it in 6 quarters since. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Balyasny Asset Management held 3,969,082 shares of Prime Medicine worth $14.6M as of Q2 2026.
  • Balyasny Asset Management sold 154,283 Prime Medicine shares in Q2 2026, an estimated $512K.
  • Prime Medicine made up 0.02% of Balyasny Asset Management's portfolio in Q2 2026, its #883 holding.
  • Balyasny Asset Management first reported a position in Prime Medicine in Q2 2024 and has held it in 6 quarters since.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.